Business SK bioscience initiates global clinical trials for GBP560
By Diplomacy Journal Lee Kap-soo SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, on Feb. 25 announced the commencement of global Phase 1/2 clinical trials for its mRNA-based Japanese encephalitis vaccine candidate, GBP560. SK Bioscience’s development of vaccine for Japanese encephalitis could not only help to protect against Japanese Encephalitis but also pave the way to the development of an mRNA technology that could be potentially adapted in a matter of weeks to develop a vaccine against a novel as-yet-identified in